Final Programme
Total Page:16
File Type:pdf, Size:1020Kb
REGIONAL WORKSHOP FINAL PROGRAMME Grand Rounds metastatic colorectal cancer 21-22 December 2017- Dubai, United Arab Emirates GENERAL INFO GENERAL GENERAL 2 INFORMATION3 Grand Rounds metastatic colorectal cancer Overview CME Provider The development of new drugs and the interdisciplinary management of the disease have resulted EXCEMED is a non-profit foundation dedicated, since the last four decades, to the development in a meaningful increase in survival for patients with metastatic colorectal cancer. As the number of high-quality medical education programmes all over the world. EXCEMED adheres to of therapeutic options increases, insights into the biology of the disease and biomarker-driven the guidelines and standards of the European Accreditation Council for Continuing Medical therapeutic strategies are expected to improve patients survival and rationalize therapeutic Education (EACCME®) which states that continuing medical education must be balanced, approaches. Recent data reveals that right- and left-sided primary colorectal cancers are clinically independent, objective and scientifically rigorous. and biologically different. Tumor sidedness has significant prognostic and predictive value that will impact on the clinical management of metastatic colorectal cancer patients. Clinical research and medical care are closely related activities and the development of an integrated learning health care system will contribute to generating and applying clinically relevant medical knowledge producing benefits for present and future patients. Learning objectives By attending this educational regional workshop, participants will be able to: • analyse colorectal cancer biology and molecular biomarkers of clinical relevance • review biomarker-driven therapeutic strategies in patients with metastatic colorectal cancer • evaluate the essentials of continuum of care approach for patients with metastatic colorectal cancer within a multidisciplinary team setting Target audience This programme is intended for oncologists and practicing clinicians who have an interest in understanding colorectal cancer biology and building individual competencies in the management of the disease. 4 5 Venue This educational regional workshop takes place at the: Hilton Conrad Hotel Sheikh Zayed Road Dubai, United Arab Emirates Language The official language of this educational regional workshop is English. FACULTY CME Provider EXCEMED - Excellence in Medical Education Programme Manager: Michela Fiuzzi T +39 06 420413 252 - F +39 06 420413 677 [email protected] Medical Advisor: Cristina Raimondi [email protected] For any logistic inquiry, please contact: Meridiano Congress International Event Manager: David Slangen T +39 06 88 595 250 - F +39 06 88595 234 [email protected] Follow us on 6 7 FACULTY Faculty Hassan Jaafar Tawam Hospital Abu Dhabi, United Arab Emirates Claus-Henning Köhne Department of Oncology and Hematology Klinikum Oldenburg Oldenburg, Germany Alberto Sobrero Department of Medical Oncology IRCCS San Martino IST Genoa, Italy Julien Taieb Department of Gastroenterology and Digestive Oncology Hôpital Européen Georges-Pompidou Assistance Publique-Hôpitaux de Paris (AP-HP) Paris Descartes University Paris, France Sally Temraz AUBMC - American University of Beirut Medical Center PROGRAMME Beirut, Lebanon Farahnaz Vafaie Zadeh Tehran University Medical School Teheran, Iran 8 PROGRAMME9 Thursday, 21 December 2017 Friday, 22 December 2017 14.00 Welcome A. Sobrero (Italy) Session I Molecular pathology and biomarkers Session II Treatment decisions in metastatic colorectal cancer (I) Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran) Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran) 14.15 L1: Critical pathways in metastatic colorectal cancer (mCRC) 09.00 L5: RAS Wild-type and BRAF Wild-type mCRC A. Sobrero (Italy) A. Sobrero (Italy) 14.45 L2: Molecular biomarkers for mCRC 09.30 L6: Primary tumor location of RAS wild-type mCRC: left vs right A. Sobrero (Italy) C.H. Köhne (Germany) 15.15 Coffee break 10.00 WORKING GROUPS: Clinical cases discussion J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany) 15.30 L3: Evidence-based recommendations for molecular testing of mCRC C.H. Köhne (Germany) 10.30 Coffee break 10.45 L7: RAS mutated and BRAF mutated mCRC 16.00 ROUNDTABLE: Key guidelines questions J. Taieb (France) J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany) 11.15 ROUNDTABLE: Frontline Strategies for Metastatic Colorectal Cancer 16.30 L4: Tumor heterogeneity and blood-based biomarkers J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany) J. Taieb (France) 12.15 WORKING GROUPS: Clinical cases discussion 17.00 Closing remarks J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany) 17.15 End of the first day 13.00 Lunch Legend L: Lecture : Q&A : Roundtable :Working Groups 10 11 Friday, 22 December 2017 Session III Treatment decisions in metastatic colorectal cancer (II) Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran) 14.00 L8: Oligometastatic disease C.H. Köhne (Germany) 14.30 L9: Therapy after progression J. Taieb (France) 15.00 WORKING GROUPS: Clinical cases discussion J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany) 15.30 L10: Spotlight - Molecular classification of CRC C.H. Köhne (Germany) 15.45 L11: Spotlight - Immunotherapy for mCRC J. Taieb (France) 16.00 Concluding remarks End of the workshop Legend L: Lecture : Q&A : Roundtable :Working Groups 12 13 Faculty disclosures EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors. The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off- label) uses of drugs as of 12 December 2017. Hassan Jaafar Claus-Henning Köhne Alberto Sobrero Julien Taieb Sally Temraz Farahnaz Vafaie Zadeh BIOGRAPHIES 14 BIOGRAPHIES Hassan Jaafar Claus-Henning Köhne Tawam Hospital Department of Oncology and Hematology Abu Dhabi, United Arab Emirates Klinikum Oldenburg Oldenburg, Germany Hassan Jaafar, is a medical consultant American society of clinical oncology) Claus-Henning Köhne studied medicine secretary. He is also a member of the in Tawam hospital (affiliated with Johns Member of the Scientific and Education at the Medical School Hannover in AIO Germany and the German Cancer Hopkins) UAE, He is being in tawam Committee of the Arab Collaborative Germany and at the University of Society. He serves as a consultant for since the year 2000 He received his Hematology and Oncology Group Glasgow in Scotland, specializing in the European Agency for Medicinal M. B. Ch. B (MD) in 1992, the internal (ACHOG). internal medicine, haematology and Products (EMA) and coordinated medicine board in 1997, and he passed oncology. He has since held senior several EORTC-trials as well as being a the Arab board exam in internal positions at the Robert-Rössle-Hospital Founding Member of the Pan-European medicine, he completed a 3 years of (Department of Haematology/Oncology Trials for ad-juvant colon Cancer fellowship in hematologyoncology and and Tumour Immunology), Humboldt- (PETACC). Prof. Köhne is a special certified as a medical hematologist University of Berlin (Charité), and at guest professor of the First Affiliated oncologist from American university the University Hospital Rostock, Clinic Hospital of Dalian Medical University/ hospital of Beirut in the year 2000. and Policlinic of Internal Medicine, China and a visiting Professor of Dalian He is the author and coauthor of more Department of Haematology/Oncology. Medical University of the Second than 40 peer reviewed papers and Prior to his current positions he Affiliated Hospital/China, where he is abstracts. He is involved in more than was appointed Professor of Medical also a member of the Sino-German- 6 ongoing phase II and phase III trials Oncology at the Medical Clinic I, Cancer-Center Oldenburg/Dalian. He regional and international and he is University Carl-Gustav-Carus of the also organizes the ESMO Preceptorship a member of the GOG (gulf oncology Technical University Dresden. He is programme for colorectal cancer. group) which conduct 2 phase II trials in a member of the European